Who
G. Walmsley Graham
Director
Company insider
Files Form 4 as: Director, Olema Pharmaceuticals; Director, Akero Therapeutics; Director, ALX Oncology Holdings.
In numbers
- Trades disclosed
- 78
- Buys
- 21
- Sells
- 4
- Bought
- $114.8M
- Sold
- $44.4M
- Companies
- 3
- Companies where not an officer
- 3
- First trade
- 8 Nov 2019
- Last trade
- 18 Jun 2026
- Last filed
- 23 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 18 Jun 2026filed 23 Jun 2026 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —29,500 at $0.00 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —93,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —1,200,000 | filing |
| 9 Dec 2025filed 9 Dec 2025 | Akero Therapeutics | SEC FORM 4 Code D | —9,398 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code M | —26,000 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code M | —15,000 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code M | —13,000 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code M | —13,000 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeuticsoption or derivative | SEC FORM 4 Code M | —23,832 at $0.00 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeutics | SEC FORM 4 Code M | $599K26,000 at $23.02 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeutics | SEC FORM 4 Code M | $122K15,000 at $8.13 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeutics | SEC FORM 4 Code M | $342K13,000 at $26.32 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeutics | SEC FORM 4 Code M | $328K13,000 at $25.20 | filing |
| 8 Oct 2025filed 10 Oct 2025 | Akero Therapeutics | SEC FORM 4 Code M | $476K23,832 at $19.97 | filing |
| 11 Jun 2025filed 13 Jun 2025 | OLMA Olema Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —24,150 at $0.00 | filing |
| 3 Jun 2025filed 5 Jun 2025 | Akero Therapeutics | SEC FORM 4 Code A | —9,398 at $0.00 | filing |
| 27 Mar 2025filed 27 Mar 2025 | Akero Therapeutics | SEC FORM 4 Bought | $2.2M50,000 at $43.55 | filing |
| 26 Mar 2025filed 27 Mar 2025 | Akero Therapeutics | SEC FORM 4 Bought | $2.5M58,691 at $43.01 | filing |
News
No headline names them, or the companies they trade most, lately.